EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

David Belada iD, Faithlore P Gardner, Ana C de Oliveira, Juan-Manuel Sancho, Elza Lomaia, David Wright, Mehmet Turgut, Elena Martynova, Zsolt Lázár, Bertrand Anz, Ming-Chung Wang, Wojciech Legiec und 6 weitere

HemaSphere · 2026-06 · 10 (6)

DOI: 10.1002/hem3.70400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 17.06.2026. Verfasst von David Belada und 17 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine - Haematology University Hospital and Faculty of Medicine Hradec Králové Czech Republic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires criteria who were ineligible for chemoimmunotherapy due to age and/or comorbidities. The primary endpoint was investigator‐assessed progression‐free survival (PFS). Patients were randomly assigned 3:1 to receive ibrutinib (560 mg) or placebo once daily until progression, together with rituximab 375 mg/m 2 weekly for 4 weeks, then every 8 weeks for 12 cycles. Overall, 445 patients were assigned to receive ibrutinib + rituximab ( n = 334) or placebo + rituximab ( n = 111). With a median follow‐up of 53.7 months, PFS was significantly improved with ibrutinib + rituximab versus placebo + rituximab (hazard ratio, 0.713 [95% CI, 0.532–0.955]; P = 0.0231; median 42.0 vs. 32.8 months), as was overall response rate (81% vs. 68%; rate ratio, 1.190 [95% CI, 1.039–1.364]; P = 0.004). Complete response rates also favored ibrutinib + rituximab (31% vs. 26%). Overall survival (OS) was immature and not significantly different between arms (hazard ratio 1.121 [95% CI, 0.771–1.631]; P = 0.5485). Grade ≥3 adverse events occurred in 78% versus 57% of patients with ibrutinib + rituximab versus placebo + rituximab, most commonly neutropenia (16% vs. 7%), pneumonia (9% vs. 5%), hypertension (8% vs. 5%), COVID‐19 (6% vs. 2%), COVID‐19 pneumonia (6% vs. 3%), and diarrhea (6% vs. 2%). In patients with previously untreated follicular lymphoma, adding ibrutinib to rituximab significantly improved PFS and response rates but did not improve OS. This trial was registered at www.clinicaltrials.gov , NCT02947347.

Autor:innen und Institutionen

  • 4th Department of Internal Medicine - Haematology University Hospital and Faculty of Medicine Hradec Králové Czech Republic.
  • Florida Cancer Specialists & Research Institute Cape Coral Florida USA.
  • Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, IDIBELL, Hospitalet Barcelona Spain.
  • ICO-Badalona Hospital Germans Trias i Pujol Badalona Spain.
  • Almazov National Medical Research Centre St. Petersburg Russia.
  • Florida Cancer Specialists & Research Institute Tampa Florida USA.

ORCID-Profile: David Belada

Zitieren

APA

Belada, D., Gardner, F. P., de Oliveira, A. C., Sancho, J. M., Lomaia, E., Wright, D., Turgut, M., Martynova, E., Lázár, Z., Anz, B., Wang, M. C., Legiec, W., Opat, S., Pailden, J., Peltier, H. M., Marturano, E., Dean, J. P., & Flinn, I. W. (2026). Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70400

Vancouver

Belada D, Gardner FP, de Oliveira AC, Sancho JM, Lomaia E, Wright D, et al. Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. HemaSphere. 2026;10(6). doi:10.1002/hem3.70400

BibTeX
@article{Belada2026,
  author = {Belada, David and Gardner, Faithlore P and de Oliveira, Ana C and Sancho, Juan-Manuel and Lomaia, Elza and Wright, David and Turgut, Mehmet and Martynova, Elena and Lázár, Zsolt and Anz, Bertrand and Wang, Ming-Chung and Legiec, Wojciech and Opat, Stephen and Pailden, Junvie and Peltier, Hillary M and Marturano, Emerenziana and Dean, James P and Flinn, Ian W},
  title = {Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {6},
  doi = {10.1002/hem3.70400}
}
Kostenlos starten →